Spironolactone treatment in patients with diabetic microalbuminuria and resistant hypertension

International Journal of Diabetes in Developing Countries

Volumn 32, Issue 1, 2012, Pages 33-36

  Kota, Sunil Kumar ^a   Jammula, Sruti ^b   Kota, Siva Krishna ^c   Meher, Lalit Kumar ^d   Modi, Kirtikumar D ^a  

^a Medwin Hospital   (India)

^b ROLAND INSTITUTE OF PHARMACEUTICAL SCIENCES   (India)

^c Central Security Hospital   (Saudi Arabia)

^d MKCG MEDICAL COLLEGE   (India)

Author keywords

Microalbuminuria; Rennin angiotensin aldosterone axis; Resistant hypertension; Spironolactone

Indexed keywords

EID: 84859910287     PISSN: 09733930     EISSN: 19983832     Source Type: Journal    
DOI: 10.1007/s13410-012-0063-5     Document Type: Article

References (25)

1. Kotchen TA. Hypertensive vascular disease. In: Fauci SA, Kasper DL, Longo DL, Braunwald E, Hauser SL, Jameson JL, et al. editors. Harrison's Principles of Internal Medicine, 17th edition; 2008. Pp- 1549-1562.
2. DA Calhoun MA Zaman MK Nishizaka 2002 Resistant hypertension Curr Hypertens Rep 4 221 228 12003705 10.1007/s11906-002-0011-8
3. AV Chobanian GL Bakris HR Black, et al. 2003 Seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure Hypertension 42 1206 1252 14656957 10.1161/01.HYP.0000107251. 49515.c2 1:CAS:528:DC%2BD3sXpsVGisL4%3D (Pubitemid 37553153)
4. UK Prospective Diabetes Study (UKPDS) Group 1998 Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 38 BMJ 317 703 713 10.1136/bmj.317.7160.703
5. C Arauz-Pacheco MA Parrott P Raskin 2003 Treatment of hypertension in adults with diabetes Diabetes Care 26 Suppl 1 S80 S82 12502624 (Pubitemid 36928963)
6. The GISEN group 1997 Randomized placebo controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric nondiabetic nephropathy Lancet 349 1857 1863 10.1016/S0140-6736(96)11445-8 (Pubitemid 27270118)
7. The ACE inhibitors in Diabetic Nephropathy Trialist Group 2001 Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin converting enzyme inhibitors? A metaanalysis of individual patient data Ann Intern Med 134 370 179
8. BM Brenner ME Cooper 2001 deZeeuw D, et al. Effect of losartan on renal and cardiovascular outcomes in patients with nephropathy due to type 2 diabetes N Engl J Med 345 861 869 11565518 10.1056/NEJMoa011161 1:CAS:528: DC%2BD3MXntlelsLk%3D
9. EJ Lewis LG Hunsicker WR Clarke, et al. 2001 Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N Eng J Med 345 851 860 10.1056/NEJMoa011303 1:CAS:528:DC%2BD3MXntlelsLg%3D
10. M Epstein 2001 Aldosterone as a mediator of progressive renal disease; pathogenetic and clinical implications Am J Kidney Dis 37 677 688 11273866 10.1016/S0272-6386(01)80115-3 1:CAS:528:DC%2BD3MXjtFWqs70%3D (Pubitemid 32273153)
11. B Pitt W Remme F Zannad, et al. 2003 Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 348 1309 1321 12668699 10.1056/NEJMoa030207 1:CAS:528:DC%2BD3sXis1ehurY%3D (Pubitemid 36384098)
12. G Mancia S Laurent E Agabiti-Rosei, et al. 2009 European society of Hypertension. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document J Hypertens 27 2121 2158 19838131 10.1097/HJH.0b013e328333146d 1:CAS:528:DC%2BD1MXhsVCjs7bM
13. MK Nishizaka MA Zaman DA Calhoun 2003 Efficacy of low dose spironolactone in subjects with resistant hypertension Am J Hypertens 16 925 930 14573330 10.1016/S0895-7061(03)01032-X 1:CAS:528:DC%2BD3sXot1Omsbk%3D (Pubitemid 37315491)
14. R Abolghasmi O Taziki 2011 Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension Saudi J Kidney Dis Transplant 22 75 78
15. DA Lane S Shah DG Beevers 2007 Low dose spironolactone in the management of resistant hypertension; a surveillance study J Hypertens 25 891 894 17351384 10.1097/HJH.0b013e328014954d 1:CAS:528:DC%2BD2sXislSrtrg%3D (Pubitemid 46398886)
16. C Xue HM Siragy 2005 Local renal aldosterone system and its regulation by salt, diabetes and angiotensin II type 1 receptor Hypertension 46 584 590 16043663 10.1161/01.HYP.0000175814.18550.c0 1:CAS:528:DC%2BD2MXptVWrsr8%3D (Pubitemid 41379384)
17. M Wehling CH Spes N Win, et al. 1998 Rapid cardiovascular action of aldosterone in man J Clin Endocrinol Metab 83 3517 3522 9768657 10.1210/jc.83.10.3517 1:CAS:528:DyaK1cXmsFKlurY%3D (Pubitemid 28500882)
18. N Chapman J Dobson S Wilson B Dahlof PS Server H Wedel NR Poulter on behalf of the Anglo Scandinavian Cardiac Outcomes Trial Investigation 2007 Effect of spironolactone on blood pressure in subjects with resistant hypertension Hypertension 49 839 845 17309946 10.1161/01.HYP.0000259805.18468.8c 1:CAS:528:DC%2BD2sXivVamt78%3D (Pubitemid 351664214)
19. TL Goodfriend 2007 Treating resistant hypertension with a neglected old drug Hypertension 49 763 764 17309945 10.1161/01.HYP.0000259806.91169.01 1:CAS:528:DC%2BD2sXkvVamsL0%3D (Pubitemid 351664201)
20. A Mahmud J Feely 2005 Aldosterone to rennin ratio, arterial stiffness and the response to aldosterone antagonism in essential hypertension Am J Hypertens 18 50 55 15691617 10.1016/j.amjhyper.2004.08.026 1:CAS:528:DC%2BD2MXit1Wms7w%3D (Pubitemid 40187349)
21. A Mahmud M Mahgoub M Hall J Feely 2005 Does aldosterone to rennin ratio predict the antihypertensive effect of aldosterone antagonist spironolactone? Am J Hypertens 18 1631 1635 16364838 10.1016/j.amjhyper.2005.06.010 1:CAS:528:DC%2BD2MXhtlCrs7nN (Pubitemid 41814688)
22. S Bianchi R Bigassi VM Compere 2005 Antagonists of aldosterone and proteinuriain patients with CKD: an uncontrolled pilot study Am J Kidney Dis 46 45 51 15983956 10.1053/j.ajkd.2005.03.007 1:CAS:528:DC%2BD2MXmvVaqurw%3D (Pubitemid 40848432)
23. A Sato K Hayashi M Naruse T Saruta 2003 Effectiveness of aldosterone blockade in patients with diabetic nephropathy Hypertension 41 64 68 12511531 10.1161/01.HYP.0000044937.95080.E9 1:CAS:528:DC%2BD38Xps1Ohu74%3D (Pubitemid 36056793)
24. K Nitta K Uchida H Nihei 2004 Spironolactone and angiotensin receptor blocker in non diabetic renal disease Am J Med 117 44 445 10.1016/j.amjmed.2004. 04.020 (Pubitemid 39369554)
25. DA Sica 2003 Eplerenone and serum potassium change relationship to renal function Am J Hypertens 16 A100 10.1016/S0895-7061(03)00335-2